Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Cost of Revenue (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cost of Revenue for 4 consecutive years, with $942211.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 34.58% to $942211.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.9 million, a 19.67% decrease, with the full-year FY2024 number at $6.0 million, up 243.7% from a year prior.
  • Cost of Revenue was $942211.0 for Q3 2025 at bioAffinity Technologies, down from $1.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.7 million in Q4 2023 to a low of $87.0 in Q1 2023.
  • A 4-year average of $850104.1 and a median of $1.0 million in 2025 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 1808452.87% in 2024, then plummeted 34.58% in 2025.
  • bioAffinity Technologies' Cost of Revenue stood at $175.0 in 2022, then soared by 951248.0% to $1.7 million in 2023, then fell by 6.17% to $1.6 million in 2024, then tumbled by 39.69% to $942211.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Cost of Revenue are $942211.0 (Q3 2025), $1.0 million (Q2 2025), and $1.4 million (Q1 2025).